BIOMAT Database Logo BIOMAT Database Logo

Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside. 1982

I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada

Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%). The time required for achieving the complete remission varied from 20 to 55 days with a median of 39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks. Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients, although they were managed by symptomatic treatment. The results indicate the effectiveness of this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.

UI MeSH Term Description Entries
D009279 Naphthacenes Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES. Tetracenes,Benz(b)Anthracenes
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015250 Aclarubicin An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity. Aclacinomycin A,Aclacin,Aclaplastin,MA-144A1,NSC-208734,MA 144A1,MA144A1,NSC 208734,NSC208734
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
[Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
August 1996, [Rinsho ketsueki] The Japanese journal of clinical hematology,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
September 1990, American journal of hematology,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Therapy of acute myelocytic leukemia. Daunomycin contrasted with a combination of cytosine arabinoside and 6-thioguanine.
December 1972, California medicine,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
June 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Vinblastine, procarbazine, and cytosine arabinoside in combination for reinduction of childhood acute myelocytic leukemia.
November 1976, Cancer treatment reports,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].
March 1995, [Rinsho ketsueki] The Japanese journal of clinical hematology,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia.
January 1977, Cancer treatment reports,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Low-dose cytosine arabinoside in relapsed acute lymphocytic leukemia.
January 1990, The American journal of medicine,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
July 1987, European journal of cancer & clinical oncology,
I Takahashi, and M Hara, and K Uchida, and K Takaoka, and S Watanabe, and M Lai, and K Hamasaki, and F Kohi, and K Kitajima, and I Kimura, and T Adachi, and S Yorimitsu, and M Tokioka, and H Sanada
Cell kinetics after high dose cytosine arabinoside in patients with acute myelocytic leukemia.
February 1990, Blut,
Copied contents to your clipboard!